The GLP-1 Revolution: From Diabetes and Obesity to Alzheimer’s and PCOS

Since GLP-1 agonists soared in popularity thanks to their powerful efficacy in diabetes and obesity, the scientific community has taken an interest in studying other potential uses for these drugs, possibly including PCOS, Alzheimer’s, Parkinson’s addiction, liver disease, and even some types of cancer.

Join Melanie G. Cree, Physician Scientist, Pediatric Endocrinologist, and Associate Professor at the University of Colorado Anschutz and Children’s Hospital Colorado and Richard Wyse, Director of Research and Development at The Cure Parkinson's Trust as they focus on where the research stands and how scientists and drugmakers are discovering an increasingly broad list of applications for these drugs—and learning more about their limitations along the way.

This ACS Webinar is moderated by Caroline Hopkins, Health & Science Reporter, Precision Medicine Online and GenomeWeb and co-produced with the Science History Institute.

The Joseph Priestley Society at the Science History Institute invites monthly speakers who are leaders from a wide variety of chemical and life science companies to promote a deeper understanding of science, technology, and industry. This year, ACS Webinars is excited to once again invite select presenters from the Joseph Priestly Society monthly series to increase our awareness of new technology from related fields that will impact the work we do as chemists.

Meet the Experts

Melanie G. Cree, Physician Scientist, Pediatric Endocrinologist and Associate Professor, University of Colorado Anschutz and Children’s Hospital Colorado

Richard Wyse, Director of Research and Development, The Cure Parkinson's Trust

Caroline Hopkins, Health & Science Reporter, Precision Medicine Online and GenomeWeb